{"id":110539,"date":"2019-05-19T00:00:50","date_gmt":"2019-05-20T01:06:15","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/110539\/"},"modified":"2019-05-20T09:06:17","modified_gmt":"2019-05-20T01:06:17","slug":"fa92c50e4a","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/110539\/","title":{"rendered":"\u80bf\u7624\u5feb\u62a5 | \u4e73\u817a\u764c\u65b0\u836f\u6a2a\u7a7a\u51fa\u4e16"},"content":{"rendered":"
\n

\"\u80bf\u7624\u5feb\u62a5
<\/p>\n


<\/p>\n

\u80bf\u7624\u65f6\u95f4\u8fd1\u671f\u5feb\u62a5\uff0c\u5e26\u7ed9\u4f60\u6700\u65b0\u7684\u8d44\u8baf\u3002<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u4e73\u817a\u764c\u65b0\u836f\u6a2a\u7a7a\u51fa\u4e16<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u7ea6 40% \u6fc0\u7d20\u53d7\u4f53\uff08HR\uff09\u9633\u6027\u3001HER2 \u9634\u6027\u7684\u4e73\u817a\u764c\u5177\u6709 PIK3CA \u7a81\u53d8\uff0cPI3K\u03b1 \u7279\u5f02\u6027\u6291\u5236\u5242 alpelisib \u5728\u65e9\u671f\u7814\u7a76\u4e2d\u9887\u5177\u6f5c\u529b\u3002\u8fd1\u65e5\uff0c\u5176 3 \u671f\u7814\u7a76\u7ed3\u679c\u5728 NEJM <\/span>\u516c\u5e03<\/span> [1]<\/sup>\u3002<\/span><\/span><\/p>\n


<\/p>\n

Alpelisib+\u6c1f\u7ef4\u53f8\u7fa4\u53ef\u4ee5\u5ef6\u957f\u63a5\u53d7\u8fc7\u5185\u5206\u6ccc\u6cbb\u7597\u7684 PIK3CA \u7a81\u53d8\u3001HR \u9633\u6027\u3001HER2 \u9634\u6027\u8fdb\u5c55\u671f\u4e73\u817a\u764c\u60a3\u8005\u7684 PFS\uff0c\u4e14\u5bf9 PIK3CA \u7a81\u53d8\u9634\u6027\u7684\u60a3\u8005\u4f3c\u4e4e\u4e5f\u6709\u4e00\u5b9a\u7597\u6548\u3002<\/span><\/p>\n


<\/p>\n

\n

\u7814\u7a76\u5bf9\u6bd4\u4e86 alpelisib 300 mg Qd+\u6c1f\u7ef4\u53f8\u7fa4 500 mg d15 Q28d \u548c\u5b89\u6170\u5242+\u6c1f\u7ef4\u53f8\u7fa4\u6cbb\u7597\u63a5\u53d7\u8fc7\u5185\u5206\u6ccc\u6cbb\u7597\u7684 HR \u9633\u6027\u3001HER2 \u9634\u6027\u8fdb\u5c55\u671f\u4e73\u817a\u764c\u60a3\u8005\u3002\u6839\u636e\u80bf\u7624\u7ec4\u7ec7 PIK3CA \u72b6\u6001\uff0c\u60a3\u8005\u5165\u7ec4\u4e24\u4e2a\u961f\u5217\u3002\u9996\u8981\u7ec8\u70b9\u662f PIK3CA \u7a81\u53d8\u961f\u5217\u7684 PFS\u3002\u6b21\u8981\u7ec8\u70b9\u662f OS \u548c\u5b89\u5168\u6027\u3002<\/span>
<\/span><\/p>\n


<\/p>\n

\u5171 572 \u540d\u60a3\u8005\u968f\u673a\uff0c\u5176\u4e2d 341 \u540d\u5177\u6709\u80bf\u7624\u7ec4\u7ec7 PIK3CA \u7a81\u53d8\u3002\u5728 PIK3CA \u7a81\u53d8\u961f\u5217\uff0c\u4e2d\u4f4d\u968f\u8bbf 20 \u4e2a\u6708\uff0c\u4e24\u7ec4\u7684\u4e2d\u4f4d PFS \u5206\u522b\u662f\u662f 11.0 \u4e2a\u6708\u548c 5.7 \u4e2a\u6708\uff08HR 0.65\uff1bP\uff1c0.001\uff09\u3002<\/span><\/p>\n


<\/p>\n

\u6ca1\u6709 PIK3CA \u7a81\u53d8\u7684\u961f\u5217\u4e2d\uff0cPFS HR 0.85\u3002\u6ca1\u6709 PIK3CA \u7a81\u53d8\u7684\u60a3\u8005\u4e2d\uff0calpelisib \u7ec4\u7684 ORR \u66f4\u4f18\uff0826.6% vs 12.8%\uff09\uff0c\u5177\u6709\u53ef\u8bc4\u4f30\u75c5\u7076\u60a3\u8005\u7684 ORR \u4e3a 35.7% vs 16.2%\u3002<\/span><\/p>\n


<\/p>\n

\u603b\u4eba\u7fa4\u4e2d\uff0c\u6700\u5e38\u89c1\u7684 3-4 \u7ea7\u4e0d\u826f\u4e8b\u4ef6\u662f\u9ad8\u8840\u7cd6\uff0836.6% vs 0.7%\uff09\u548c\u76ae\u75b9\uff089.9% vs 0.3%\uff09\u30023 \u7ea7\u8179\u6cfb\u53d1\u751f\u7387 6.7% vs 0.3%\uff0c\u6ca1\u6709 4 \u7ea7\u8179\u6cfb\u53d1\u751f\u3002\u56e0\u4e0d\u826f\u4e8b\u4ef6\u505c\u836f\u7684\u60a3\u8005\u6bd4\u4f8b\u662f 25.0% vs 4.2%\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u767d\u86cb\u767d\u7d2b\u6749\u9187\u6539\u5584\u65e9\u671f\u4e73\u817a\u764c\u9884\u540e<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

GBG 69-GeparSepto \u7814\u7a76\u8bc1\u5b9e\u548c\u7d2b\u6749\u9187\u6bcf\u5468\u65b9\u6848\u65b0\u8f85\u52a9\u6cbb\u7597\u76f8\u6bd4\uff0c\u6bcf\u5468\u65b9\u6848\u7684\u767d\u86cb\u767d\u7ed3\u5408\u7d2b\u6749\u9187\uff08nab-PTX\uff09\u4e0d\u4ec5\u663e\u8457\u6539\u5584\u4e73\u817a\u764c\u60a3\u8005\u7684\u75c5\u7406\u5b8c\u5168\u7f13\u89e3\u7387\uff08pCR\uff09\uff0c\u8fd8\u6539\u5584\u60a3\u8005\u7684 DFS\u3002<\/span><\/p>\n


<\/p>\n

\u8fd9\u4e00\u957f\u671f\u7ed3\u5c40\u6570\u636e\u53d1\u8868\u5728 5 \u6708 13 \u65e5\u7684 JCO \u4e0a [2]<\/sup>\u3002<\/span><\/p>\n


<\/p>\n

\n

1206 \u540d\u4e73\u817a\u764c\u60a3\u8005\u968f\u673a\uff081:1\uff09\u63a5\u53d7 12 \u5468 nab-PTX 150 mg\/m2\uff08\u65b9\u6848\u4fee\u6539\u540e\u4e3a 125 mg\/m2\uff09\uff08n = 606\uff09\u6216 PTX 80 mg\/m2\uff08n = 600\uff09\u6cbb\u7597\uff0c\u5e8f\u8d2f 4 \u5468\u671f\u8868\u67d4\u6bd4\u661f 90 mg\/m2+\u73af\u78f7\u9170\u80fa 600 mg\/m2 Q3W \u6cbb\u7597\u3002HER2 \u9633\u6027\u60a3\u8005\u63a5\u53d7\u66f2\u59a5\u73e0\u5355\u6297+\u5e15\u59a5\u73e0\u5355\u6297\u6cbb\u7597 1 \u5e74\u3002<\/span>
<\/span><\/p>\n


<\/p>\n

\u4e2d\u4f4d\u968f\u8bbf 49.6 \u4e2a\u6708\u3002\u63a5\u53d7 nab-PTX \u6cbb\u7597\u7684\u60a3\u8005 4 \u5e74\u65e0\u4fb5\u88ad\u75be\u75c5\u751f\u5b58\u7387\uff08iDFS\uff09\u663e\u8457\u9ad8\u4e8e PTX \u6cbb\u7597\u7ec4\uff0884.0% vs 76.3%\uff0cHR 0.66\uff0cP = 0.002\uff09\uff0c\u800c\u4e24\u7ec4 OS \u7387\u6ca1\u6709\u663e\u8457\u5dee\u5f02\uff0889.7% vs 87.2%\uff0cHR 0.82\uff0cP = 0.260\uff09\u3002<\/span><\/p>\n


<\/span><\/p>\n

\u957f\u671f\u968f\u8bbf\u53d1\u73b0 125 mg\/m2 \u5242\u91cf nab-PTX \u7684\u5468\u56f4\u611f\u89c9\u795e\u7ecf\u75c5\u7684\u4e2d\u4f4d\u7f13\u89e3\u65f6\u95f4\u6bd4 150 mg\/m2 \u5242\u91cf\u663e\u8457\u7f29\u77ed\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u80c3\u764c\u4e00\u7ebf\u5316\u7597\uff1a\u591a\u672a\u5fc5\u597d<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

5 \u6708 14 \u65e5\uff0cLancet Gastroenterol Hepatol \u520a\u767b\u4e86\u65e5\u672c\u7684 JCOG1013 \u7814\u7a76\u7ed3\u679c\uff0c\u5bf9\u6bd4\u591a\u897f\u4ed6\u8d5b+\u987a\u94c2+S-1 \u548c\u987a\u94c2+S-1 \u6cbb\u7597\u8fdb\u5c55\u671f\u80c3\u764c\u7684\u7597\u6548\u548c\u5b89\u5168\u6027 [3]<\/sup>\u3002<\/span><\/p>\n


<\/p>\n

\u7814\u7a76\u53d1\u73b0\u591a\u897f\u4ed6\u8d5b\u7684\u52a0\u5165\u4e0d\u6539\u5584\u521d\u6cbb\u80c3\u764c\u60a3\u8005\u7684 OS\u3002\u56e0\u6b64\uff0c\u987a\u94c2+S-1 \u4f9d\u65e7\u662f\u6807\u51c6\u4e00\u7ebf\u5316\u7597\u3002<\/span><\/p>\n


<\/p>\n

\n

741 \u540d\u60a3\u8005\u968f\u673a\uff081:1\uff09\u63a5\u53d7\u591a\u897f\u4ed6\u8d5b 40 mg\/ m2+\u987a\u94c2 60 mg\/ m2 d1+S-1 40-60 mg Bid\u00d72 \u5468 Q4W\uff08n = 370\uff09\uff0c\u6216\u987a\u94c2 60 mg\/ m2 d8+S-1 40-60 mg Bid\u00d73 \u5468 Q5W\uff08n = 371\uff09\u3002\u9996\u8981\u7ec8\u70b9\u662f ITT \u4eba\u7fa4\u7684 OS\u3002<\/span><\/p>\n


<\/p>\n

\u4e24\u7ec4\u7684 OS \u5206\u522b\u662f 14.2 \u6708 vs 15.3 \u6708\uff08HR 0.99\uff1bP = 0.47\uff09\u3002\u6700\u5e38\u89c1 3 \u7ea7\u4ee5\u4e0a\u4e0d\u826f\u4e8b\u4ef6\u662f\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0859% vs 32%\uff09\uff0c\u767d\u7ec6\u80de\u51cf\u5c11\uff0834% vs 16%\uff09\u548c\u538c\u98df\uff0826% vs 22%\uff09\u3002\u4e24\u7ec4\u5404\u6709 3 \u4f8b\u548c 1 \u4f8b\u6cbb\u7597\u76f8\u5173\u6b7b\u4ea1\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u51cf\u7624\u672f+\u8179\u8154\u70ed\u704c\u6ce8\u6709\u6548\u6cbb\u7597\u80c3\u764c\u8179\u819c\u8f6c\u79fb<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u80c3\u764c\u8179\u819c\u8f6c\u79fb\u9884\u540e\u4e0d\u826f\uff0c\u51cf\u7624\u672f\uff08CRS\uff09\u662f\u5f88\u6709\u524d\u9014\u7684\u6cbb\u7597\u65b9\u6cd5\uff0c\u4f46\u662f\u8179\u8154\u70ed\u704c\u6ce8\u5316\u7597\uff08HIPEC\uff09\u7684\u7597\u6548\u4f9d\u65e7\u5b58\u5728\u4e89\u8bae\u3002CYTO-CHIP \u7814\u7a76\u6bd4\u8f83\u4e86 CRS-HIPEC \u5bf9\u6bd4\u5355\u7eaf CRS \u6cbb\u7597\u80c3\u764c\u8179\u819c\u8f6c\u79fb\u7684\u7597\u6548\uff0c\u7ed3\u679c\u53d1\u8868\u5728 JCO \u4e0a [4]<\/sup>\u3002<\/span><\/p>\n


<\/p>\n

\u548c\u5355\u7eaf CRS \u76f8\u6bd4\uff0cCRS-HIPEC \u53ef\u6539\u5584 OS \u548c RFS\uff0c\u4e14\u4e0d\u589e\u52a0\u989d\u5916\u7684\u5e76\u53d1\u75c7\u6216\u6b7b\u4ea1\u7387\u3002\u5982\u679c\u53ef\u80fd\u5b8c\u6210 CRS\uff0cCRS-HIPEC \u53ef\u80fd\u662f\u7ecf\u8fc7\u4e25\u683c\u7b5b\u9009\u60a3\u8005\u7684\u6709\u4ef7\u503c\u7684\u6cbb\u7597\u65b9\u5f0f\u3002<\/span><\/p>\n


<\/p>\n

\n

\u524d\u77bb\u6027\u6570\u636e\u5e93\u4e2d\u53d1\u73b0 277 \u540d\u884c\u6839\u6cbb\u6027\u5b8c\u5168 CRS \u6cbb\u7597\u7684\u80c3\u764c\u8179\u819c\u8f6c\u79fb\u60a3\u8005\u3002\u5176\u4e2d 180 \u540d\u884c CRS-HIPEC\uff0c97 \u540d\u884c\u5355\u7eaf CRS\u3002\u4f7f\u7528\u8179\u819c\u764c\u6307\u6570\u8bc4\u4f30\u80bf\u7624\u8d1f\u8377\uff0cCox \u6bd4\u4f8b\u98ce\u9669\u56de\u5f52\u6a21\u578b\u8bc4\u4f30\u7597\u6548\u3002<\/span><\/p>\n


<\/p>\n

CRS-HIPEC \u53ef\u6539\u5584 OS\uff0c\u4e24\u7ec4\u7684\u4e2d\u4f4d OS \u5206\u522b\u662f 18.8 \u6708 vs 12.1 \u6708\uff0c3 \u5e74 OS \u7387\u5206\u522b\u662f 26.21% vs 10.82%\uff0c5 \u5e74 OS \u7387 19.87% vs 6.43%\u30023 \u5e74 RFS \u7387\u662f 20.40% vs 5.87%\uff0c5 \u5e74 RFS \u7387\u662f 17.05% vs 3.76%\u3002<\/span><\/p>\n


<\/p>\n

\u4e24\u7ec4\u7684 90 \u5929\u6b7b\u4ea1\u7387\uff087.4% vs 10.1%\uff09\u548c\u4e25\u91cd\u5e76\u53d1\u75c7\u7387\uff0853.7% vs 55.3%\uff09\u6ca1\u6709\u5dee\u522b\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u5c3c\u8fbe\u5c3c\u5e03\u6cbb\u7597\u80f8\u819c\u95f4\u76ae\u7624\u2014\u2014\u5931\u8d25\uff01<\/strong><\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\u5c3c\u8fbe\u5c3c\u5e03\u662f\u4e00\u79cd\u591a\u9776\u70b9\u6fc0\u9176\u6291\u5236\u5242\u3002\u5c3c\u8fbe\u5c3c\u5e03\u8054\u5408\u57f9\u7f8e\u66f2\u585e-\u987a\u94c2\u6cbb\u7597\u6076\u6027\u80f8\u819c\u95f4\u76ae\u7624\u7684 LUME-Meso \u7814\u7a76\u7684 3 \u671f\u90e8\u5206\u63ed\u6653\uff0c\u4e8e 5 \u6708 15 \u65e5\u53d1\u8868\u5728 Lancet Respir Med \u4e0a[5]<\/sup>\u3002<\/span><\/p>\n


<\/p>\n

\u7814\u7a76\u672a\u8fbe\u5230\u9996\u8981\u7ec8\u70b9\uff0c\u548c\u5b89\u6170\u5242\u76f8\u6bd4\uff0c\u5c3c\u8fbe\u5c3c\u5e03\u7684\u52a0\u5165\u4e0d\u80fd\u6539\u5584PFS\u3002<\/span><\/p>\n


<\/p>\n

\n

\u5c3c\u8fbe\u5c3c\u5e03\u662f\u9488\u5bf9 VEGFR1-3\uff0cPDGFR\u03b1 \u548c \u03b2\uff0cFGFR1-3 \u548c Src \u548c Abl \u6fc0\u9176\u7684\u9776\u5411\u836f\uff0c\u800c\u8fd9\u4e9b\u901a\u8def\u548c\u6076\u6027\u80f8\u819c\u95f4\u76ae\u7624\u90fd\u76f8\u5173\u3002LUME-Meso \u8bd5\u9a8c\u7684 3 \u671f\u90e8\u5206\u7814\u7a76\u57f9\u7f8e\u66f2\u585e+\u987a\u94c2\u8054\u5408\u5c3c\u8fbe\u5c3c\u5e03\u6cbb\u7597\u672a\u5207\u9664\u7684\u6076\u6027\u80f8\u819c\u95f4\u76ae\u7624\u60a3\u8005\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002<\/span>
<\/span><\/span><\/p>\n


<\/p>\n

458 \u540d\u521d\u6cbb\u60a3\u8005\u968f\u673a 1:1 \u63a5\u53d7 6 \u5468\u671f\u57f9\u7f8e\u66f2\u585e 500 mg\/m2+\u987a\u94c2 75 mg\/ m2 d1 Q21d \u6cbb\u7597\uff0c\u8054\u5408\u5c3c\u8fbe\u5c3c\u5e03 200 mg Bid\uff08n = 229\uff09\u6216\u5b89\u6170\u5242\uff08n = 229\uff09d2-21 \u6cbb\u7597\u3002\u9996\u8981\u7ec8\u70b9\u662f ITT \u4eba\u7fa4\u7684 PFS\u3002<\/span><\/p>\n


<\/p>\n

\u4e24\u7ec4\u7684 PFS \u6ca1\u6709\u663e\u8457\u5dee\u5f02\uff08\u4e2d\u4f4d\uff0c6.8 \u6708 vs 7.0 \u6708\uff0cHR 1.01\uff1bP = 0.91\uff09\u3002\u4e24\u7ec4\u6700\u5e38\u89c1\u7684 3 \u7ea7\u4ee5\u4e0a\u4e0d\u826f\u4e8b\u4ef6\u662f\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\uff0832% vs 24%\uff09\u3002\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\u53d1\u751f\u7387 44% vs 39%\u3002\u81f3\u5c11 5% \u60a3\u8005\u53d1\u751f\u7684\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\u662f\u80ba\u6813\u585e\uff086% vs 3%\uff09\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n

\n
\n
\n
\n

\u5c3d\u4fe1\u6307\u5357\u4e0d\u5982\u65e0\u6307\u5357<\/span><\/p>\n<\/section>\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

<\/span><\/p>\n

ASCO \u548c ESMO \u90fd\u6709\u5404\u81ea\u7684\u8bc4\u5206\u4f53\u7cfb\uff0c\u4f46\u8fd8\u4e0d\u6e05\u695a\u8fd9\u4e9b\u4e34\u5e8a\u83b7\u76ca\u8bc4\u5206\u7b97\u6cd5\u662f\u4e0d\u662f\u80fd\u591f\u8861\u91cf\u7edd\u5bf9\u6216\u76f8\u5bf9\u751f\u5b58\u83b7\u76ca\u3002\u8fd1\u65e5\uff0cJAMA Oncol \u520a\u767b\u4e00\u7bc7 meta \u5206\u6790\uff0c\u8bc4\u4f30\u6307\u5357\u8bc4\u5206\u548c\u771f\u5b9e\u83b7\u76ca\u7684\u76f8\u5173\u6027 [6]<\/sup>\u3002<\/span><\/p>\n

\u5206\u6790\u53d1\u73b0\u8fd9\u4e24\u4e2a\u4f53\u7cfb\u90fd\u4e0d\u80fd\u4e00\u81f4\u5730\u8861\u91cf\u7edd\u5bf9\u751f\u5b58\u83b7\u76ca\u3002\u6307\u5357\u7b97\u6cd5\u4e2d\u751f\u5b58\u7597\u6548\u90e8\u5206\u5e94\u8003\u8651\u7eb3\u5165\u5176\u4ed6\u7edd\u5bf9\u4e34\u5e8a\u83b7\u76ca\u6307\u6807\u3002<\/span><\/p>\n

\n

\u4f7f\u7528\u7f8e\u56fd FDA \u8840\u6db2\u548c\u80bf\u7624\u83b7\u6279\u548c\u5b89\u5168\u901a\u544a\u6570\u636e\u5e93\uff0c\u56de\u987e\u6027\u67e5\u627e 3 \u671f\u968f\u673a\u5bf9\u7167\u7814\u7a76\uff0c\u63d0\u53d6\u6570\u636e\u884c meta \u5206\u6790\u3002<\/span>
<\/span><\/p>\n


<\/p>\n

\u7edd\u5bf9\u751f\u5b58\u83b7\u76ca\u4e0a\uff0cESMO \u548c\u9650\u5236\u5e73\u5747\u751f\u5b58\u65f6\u95f4\uff08RMST\uff09\u5177\u6709\u4e2d-\u4f4e\u5ea6\u76f8\u5173\u6027\uff0c\u548c\u4e2d\u4f4d\u751f\u5b58\u5dee\u5f02\u5177\u6709\u4e2d-\u9ad8\u5ea6\u76f8\u5173\u6027\u3002ASCO \u548c\u7edd\u5bf9\u83b7\u76ca\u5177\u6709\u4f4e-\u4e2d\u5ea6\u76f8\u5173\u6027\u3002\u76f8\u5bf9\u751f\u5b58\u83b7\u76ca\u65b9\u9762\uff0cESMO \u4f4e\u5ea6\u76f8\u5173\uff0c\u800c ASCO \u5177\u6709\u9ad8\u5ea6\u76f8\u5173\u3002<\/span><\/p>\n


<\/p>\n

ASCO \u548c ESMO \u7684\u7b97\u6cd5\u4e2d\u751f\u5b58\u7597\u6548\u90e8\u5206\u5e94\u8003\u8651\u7eb3\u5165\u76f4\u63a5\u6d4b\u91cf RMST \u5dee\u5f02\u7b49\u7edd\u5bf9\u4e34\u5e8a\u83b7\u76ca\u3002<\/span><\/p>\n<\/section>\n

\uff08\u6ed1\u52a8\u67e5\u770b\u7814\u7a76\u8be6\u60c5\uff09<\/span><\/p>\n


<\/p>\n


<\/p>\n

\n
\n
\n

\u7f16\u8f91\uff1adecie | \u8d23\u4efb\u7f16\u8f91\uff1a\u738b\u5f18<\/span><\/p>\n

\u6295\u7a3f\uff1adecie@qq.com
<\/span><\/p>\n

\u9898\u56fe\uff1a\u7ad9\u9177\u6d77\u6d1bplus<\/span><\/span><\/p>\n


<\/p>\n


<\/p>\n

\u63a8\u8350\u9605\u8bfb\uff1a<\/strong><\/span><\/p>\n

3 \u4e2a\u75c5\u4f8b\u6559\u4f60\u641e\u5b9a\u764c\u75c7\u76f8\u5173\u9759\u8109\u8840\u6813\u6813\u585e<\/a><\/h2>\n

\u518d\u5582\u517b\u7efc\u5408\u5f81\uff1a<\/span><\/a>\u8425\u517b\u8865\u5145\u4e0d\u80fd\u64cd\u4e4b\u8fc7\u6025<\/a><\/span><\/p>\n

\u6fc0\u7d20\u53d7\u4f53\u9633\u6027\u4e73\u817a\u764c\u6cbb\u7597\u53c8\u6709\u65b0\u65b9\u6848<\/a><\/p>\n

\u4e73\u817a\u764c 21 \u57fa\u56e0\u68c0\u6d4b\u7684\u90a3\u4e9b\u4e8b<\/a><\/p>\n


<\/a><\/p>\n

\"\u80bf\u7624\u5feb\u62a5
<\/p>\n<\/section>\n<\/section>\n<\/section>\n

\n
\n
\n

\"\u80bf\u7624\u5feb\u62a5<\/p>\n

\u53c2\u8003\u6587\u732e<\/span><\/p>\n

1. Andr\u00e9 F et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer. N Engl J Med 2019 May 16<\/span><\/p>\n

2. Untch M et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69\u2013GeparSepto. J Clin Oncol 2019 May 13<\/span><\/p>\n

3. Yamada PY et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol 2019 May 14<\/span><\/p>\n

4. Bonnot PE et al. Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. J Clin Oncol 2019 May 14<\/span><\/p>\n

5. Scagliotti GV et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med 2019 May 15<\/span><\/p>\n

6. Saluja R et al. Assessment of Whether the American Society of Clinical Oncology\u2019s Value Framework and the European Society for Medical Oncology\u2019s Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: A Meta-analysis of Randomized Clinical Trials. JAMA Oncol 2019 May 16<\/span><\/p>\n<\/section>\n<\/section>\n<\/section><\/div>\n","protected":false},"excerpt":{"rendered":"

\u80bf\u7624\u65f6\u95f4\u8fd1\u671f\u5feb\u62a5\uff0c\u5e26\u7ed9\u4f60\u6700\u65b0\u7684\u8d44\u8baf\u3002 \u4e73\u817a\u764c\u65b0\u836f\u6a2a\u7a7a\u51fa\u4e16 \u7ea6 40% \u6fc0\u7d20\u53d7\u4f53\uff08HR\uff09\u9633\u6027\u3001HER2 \u9634\u6027\u7684\u4e73 […]<\/p>\n","protected":false},"author":1,"featured_media":110540,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/110539"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=110539"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/110539\/revisions"}],"predecessor-version":[{"id":110544,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/110539\/revisions\/110544"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/110540"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=110539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=110539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=110539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}